# IRB Protocol Template — Federated AI Oncology Trial

## Protocol Title
Federated Machine Learning for Multi-Site Oncology Treatment Prediction Using Physical AI Systems

## Protocol Number
PAI-FL-_______________

## Principal Investigator
_______________

## Version / Date
v1.0 / _______________

---

## 1. Study Summary

This protocol describes a multi-institution federated learning study that trains AI models on oncology clinical data without centralizing patient records. Each participating site trains models locally and shares only encrypted model parameter updates with a central coordinator. The study integrates physical AI components including surgical robotic telemetry and patient digital twins.

## 2. Background and Rationale

- Oncology treatment outcomes vary across institutions due to patient population differences.
- Centralized data sharing is impractical due to HIPAA, GDPR, and institutional data governance requirements.
- Federated learning enables collaborative model development while preserving patient privacy.
- Physical AI systems (surgical robots, digital twins) generate valuable data that can improve treatment prediction when combined across sites.

## 3. Objectives

### Primary
- Train a federated AI model for oncology treatment response prediction across ≥2 clinical sites.

### Secondary
- Evaluate differential privacy impact on model accuracy.
- Assess cross-site generalization of treatment response models.
- Validate physical AI integration (robotic telemetry features) for outcome prediction.

## 4. Study Design

- **Type:** Multi-site retrospective analysis with federated learning.
- **Duration:** _____ months.
- **Sites:** _____ participating institutions.
- **Patients:** De-identified records from _____ patients per site (approximately).

## 5. Data Collection and Privacy

### 5.1 Data Types
- De-identified clinical features (age bracket, tumor stage, biomarkers).
- Treatment history and outcomes.
- De-identified surgical robotic telemetry (force, trajectory, timing).
- Digital twin simulation outputs.

### 5.2 De-Identification
All data will be de-identified using the platform's automated pipeline, which removes or replaces the 18 HIPAA identifiers.

### 5.3 Privacy Safeguards
- Differential privacy (epsilon ≤ _____ per round).
- Secure aggregation of model updates.
- No raw patient data leaves any participating site.

## 6. Risk Assessment

### Minimal Risk
- No direct patient intervention.
- All data is retrospective and de-identified.
- Model parameters do not contain individually identifiable information (verified by differential privacy bounds).

### Potential Risks
- Theoretical risk of model inversion attacks (mitigated by DP and secure aggregation).
- Risk of biased model if site populations are not representative (mitigated by fairness audits).

## 7. Informed Consent

- Waiver of informed consent is requested for retrospective de-identified data analysis.
- If prospective data collection is included, the standard consent template (see DUA templates) must be used.

## 8. Data Monitoring

- Automated compliance checks run before each training round.
- Audit logs are maintained for all data access events.
- Quarterly reports will be provided to the IRB.

## 9. Publication Plan

- Aggregate results will be published in peer-reviewed journals.
- No individual patient data or site-specific model parameters will be disclosed.
- All participating sites will be acknowledged.
